NASDAQ:VYNE - Nasdaq - US92941V3087 - Common Stock - Currency: USD
NASDAQ:VYNE (5/7/2025, 2:52:44 PM)
1.36
+0.01 (+0.74%)
The current stock price of VYNE is 1.36 USD. In the past month the price decreased by -12.34%. In the past year, price decreased by -49.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 56.25 | 733.75B | ||
JNJ | JOHNSON & JOHNSON | 15.63 | 377.98B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.48 | 298.28B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.44 | 220.54B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.85 | 217.37B | ||
MRK | MERCK & CO. INC. | 10.13 | 198.57B | ||
PFE | PFIZER INC | 7.09 | 129.03B | ||
SNY | SANOFI-ADR | 13.57 | 127.57B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.46 | 96.48B | ||
GSK | GSK PLC-SPON ADR | 6.75 | 74.99B | ||
ZTS | ZOETIS INC | 25.76 | 69.18B | ||
HLN | HALEON PLC-ADR | 22.02 | 48.65B |
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 13 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807 US
CEO: David Domzalski
Employees: 10
Phone: 18007757936
The current stock price of VYNE is 1.36 USD. The price increased by 0.74% in the last trading session.
The exchange symbol of VYNE THERAPEUTICS INC is VYNE and it is listed on the Nasdaq exchange.
VYNE stock is listed on the Nasdaq exchange.
10 analysts have analysed VYNE and the average price target is 6.31 USD. This implies a price increase of 364.06% is expected in the next year compared to the current price of 1.36. Check the VYNE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VYNE THERAPEUTICS INC (VYNE) has a market capitalization of 20.69M USD. This makes VYNE a Nano Cap stock.
VYNE THERAPEUTICS INC (VYNE) currently has 10 employees.
VYNE THERAPEUTICS INC (VYNE) has a resistance level at 1.43. Check the full technical report for a detailed analysis of VYNE support and resistance levels.
The Revenue of VYNE THERAPEUTICS INC (VYNE) is expected to decline by -62.5% in the next year. Check the estimates tab for more information on the VYNE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VYNE does not pay a dividend.
VYNE THERAPEUTICS INC (VYNE) will report earnings on 2025-05-07.
VYNE THERAPEUTICS INC (VYNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
The outstanding short interest for VYNE THERAPEUTICS INC (VYNE) is 1.39% of its float. Check the ownership tab for more information on the VYNE short interest.
ChartMill assigns a fundamental rating of 3 / 10 to VYNE. The financial health of VYNE is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months VYNE reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 86.65% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -59.54% | ||
ROE | -76.48% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to VYNE. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -27.5% and a revenue growth -62.5% for VYNE